Breaking: Recursion and Exscientia to merge in one of AI bio's biggest M&A deals
Recursion and Exscientia agreed to merge in an all-stock deal, the two AI-focused biotechs said Thursday morning. The merger is one of the biggest M&A deals for the nascent but fast-evolving AI...
View ArticleRoivant to 'unveil' pipeline addition next month; Bavarian Nordic gets $156M...
Plus, news about Evotec, Bristol Myers Squibb and Precigen: Roivant hints at another deal: The drugmaker may make an addition to its pipeline, saying it has plans for “unveiling one such program next...
View ArticleQ&A: PhRMA CEO Stephen Ubl on the IRA, challenges to the FDA’s authority and...
As we approach the 2024 presidential election, Stephen Ubl, president and CEO of the pharmaceutical industry’s DC-based trade group PhRMA, said “the political process has really never been more...
View ArticleTIGIT drugs take another hit as Merck stops Phase 3 lung cancer trial for...
Merck is winding down a late-stage test of its anti-TIGIT candidate vibostolimab in small-cell lung cancer after it showed early signs of poor efficacy, in another blow to the TIGIT space. The Phase 3...
View ArticleIntellia’s gene editing therapy succeeds in Phase 2 genetic swelling...
Intellia Therapeutics’ CRISPR-based treatment for a rare genetic disease called hereditary angioedema reduced the bouts of swelling associated with the disease in a mid-stage test, the company...
View ArticleFDA approves Amneal Pharma's extended-release Parkison's treatment
Amneal Pharmaceuticals’ extended-release capsule for Parkinson’s disease has been approved by the FDA following an initial rejection last year. The treatment, which will be marketed as Crexont, is a...
View ArticleApellis and Sobi land another late-stage win for rare kidney disease drug
Empaveli, the kidney disease drug from Apellis Pharmaceuticals and Sobi, reported a Phase 3 trial success that could help the treatment keep pace with a competing therapy from Novartis. On Thursday,...
View ArticleClik here to view.
Lilly’s anti-tau pill for Alzheimer’s fails in Phase 2 study
One month after the long-awaited approval of its first Alzheimer’s drug, Eli Lilly said that another experimental medicine aimed at slowing dementia failed in a Phase 2 study of 330 people. The drug,...
View ArticleClik here to view.
FDA approves Citius Pharma's non-Hodgkin lymphoma drug Lymphir
Citius Pharmaceuticals scored an approval from the FDA on Thursday for its treatment for a rare form of non-Hodgkin lymphoma, bringing to the market a reformulation of a cancer immunotherapy that was...
View ArticleWuXi Biologics gains some traction in Europe in the face of Biosecure threat...
WuXi Biologics appears to be making some progress in Europe in recent days, after securing a new biotech partner and EMA certifications for its manufacturing sites in China. On Thursday, the German...
View ArticleLilly contributes to isotope supplier fundraise; Layoffs at Ajinomoto
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Eli Lilly is injecting some funding into Ionetix for the isotope...
View ArticleClik here to view.
Lilly says to ‘take some caution’ on other companies’ early-stage obesity...
After posting a blowout quarter of financial results, Eli Lilly has almost made the obesity business look easy. But amid investors’ enthusiasm for weight loss drugs, the company’s top scientist warned...
View ArticleAldeyra to resubmit dry eye disease drug this year following positive Phase 3...
Aldeyra Therapeutics plans to make another run at FDA approval for its dry eye disease drug after the agency handed down a complete response letter last year. The company said Thursday that a Phase 3...
View ArticlePurdue’s emergency opioid overdose treatment is approved by the FDA
Purdue Pharma on Wednesday won FDA approval for its emergency treatment for opioid overdose as the company attempts to distance itself from its role in the opioid epidemic. The nalmefene hydrochloride...
View ArticleGilead shells out $320M to J&J to buy out rare liver disease drug royalties
Gilead is spending $320 million to buy out Johnson & Johnson’s global royalties for primary biliary cholangitis drug seladelpar a week before the FDA is expected to decide whether to approve it. In...
View ArticleClik here to view.
AN2 Therapeutics undergoes makeover after late-stage lung disease trial...
AN2 Therapeutics said it will shut down a late-phase study of its lead candidate in bacterial lung disease and then go through a company overhaul. The placebo-controlled Phase 2/3 trial was testing the...
View ArticleClik here to view.
Bill Haney's Dragonfly nabs former Cerevel CFO; Cellectis' new CMO
Susan Altschuller → Bill Haney’s Dragonfly Therapeutics has brought aboard Susan Altschuller as CFO. Altschuller’s résumé includes other finance chief roles at Cerevel Therapeutics and ImmunoGen, which...
View ArticleExclusive: MIT spinout launches with focus on improving DNA payloads for gene...
We often imagine DNA as a stringlike molecule that’s easily scrunched up. But our six-foot-long genomes only fit inside our cells thanks to an intricate spooling system. Left on its own, DNA’s famed...
View ArticleClik here to view.
Merck pays $700M for clinical-stage CD3xCD19 bispecific antibody
Merck is making its fourth acquisition of the year, this time buying a single asset from a Shanghai-based cancer drug developer. The New Jersey pharma giant said Friday it is dishing out $700 million...
View ArticleFDA lifts hold on 4DMT's Fabry gene therapy
The FDA lifted an 18-month clinical hold on 4D Molecular Therapeutics’ cardiomyopathy gene therapy for Fabry disease. The biotech said Thursday it expects to resume enrollment in the Phase 1/2 INGLAXA...
View Article